Cytrx Corporation

Tuesday, September 23, 2008

Steven Kriegsman

Director, President and CEO

Steven A. Kriegsman has been a Director, President and Chief Executive Officer of CytRx Corporation (Nasdaq: CYTR) since July 2002. He also serves as a Director of RXi Pharmaceuticals Inc. (Nasdaq: RXII) and Chairman of its Compensation Committee. Mr. Kriegsman also serves as a Director of Hythiam, Inc (Nasdaq: HYTM) and Chairman of its Audit Committee. He previously served as a Director and Chairman of Global Genomics from June 2000 until its merger with CytRx Corporation in July 2002. Mr. Kriegsman is the Chairman of the Board and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. Mr. Kriegsman has a B.S. degree with honors from New York University in accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. From June 2003 until February 2008, he served as a Director, and he is the former Chairman of the Audit Committee of Bradley Pharmaceuticals, Inc. In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr. Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, and the Palisades-Malibu YMCA.

The webcast interview contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx''s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date of the interview. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.